Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and efficacy of the oral version of its investigational obesity drug VK2735.

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report ... its leading GLP1/GIP portfolio in obesity, with significant developments including ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.